<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01078571</url>
  </required_header>
  <id_info>
    <org_study_id>P10-077</org_study_id>
    <nct_id>NCT01078571</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of Adalimumab in Patients Diagnosed With Rheumatoid Arthritis</brief_title>
  <acronym>DALI</acronym>
  <official_title>Safety and Effectiveness of Adalimumab (HUMIRA®) in Patients Diagnosed With Rheumatoid Arthritis (DALI Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adalimumab is one of the pharmacological treatments for rheumatoid arthritis (RA) of more
      recent marketing authorization, and as a result of this, there are only efficacy and safety
      data from clinical trials with controlled conditions.The study will evaluate the safety and
      effectiveness of adalimumab in the common clinical practice of RA treatment in Spain, with
      several types of patients showing concomitant treatments or diseases and compliance. Among
      the tumor necrosis factor antagonists safety studies, adalimumab safety has been the less
      investigated in the common clinical practice because of, as a result of its recent marketing,
      it was not included in the BIOBADASER (Data Base for Biological Products in Spain,
      Rheumatology Spanish Society), Biologic Products Database of the Spanish Society of
      Rheumatology ) in which was determined an association between infliximab therapy and the risk
      of developing active tuberculosis. To ensure the maintaining of the strict common physician
      practice (no prescription induction), and following the recommendations of the SER (Sociedad
      Española de Reumatología, Spanish Society of Rheumatology) consensus documents, it will be
      selected only those patients that were already in treatment with adalimumab (HUMIRA),(except
      patients involved in clinical studies with Adalimumab), and had shown good response, or those
      that fulfilled treatment indication in accordance with the SER recommendations and following
      the Summary of Products Characteristics of adalimumab (HUMIRA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main objective

        -  To evaluate safety and tolerability of adalimumab (HUMIRA) treatment, administered both
           in monotherapy and combined therapy, in rheumatoid arthritis patients under usual
           practice conditions.

      Secondary objectives

        -  To evaluate the effectiveness of the adalimumab (HUMIRA) treatment, administered both in
           monotherapy and combined therapy, in rheumatoid arthritis patients under usual practice
           conditions in accordance with SER recommendations:

        -  To evaluate the life quality associated to the adalimumab (HUMIRA) treatment,
           administered both in monotherapy and combined therapy, in rheumatoid arthritis patients
           under usual practice conditions.

        -  To describe the profile of patients who are in treatment with adalimumab (HUMIRA)
           biological therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of Adalimumab Treatment. Adverse Events: Medical Occurrence in a Patient or Clinical Investigation Subject Administered a Pharmaceutical Product and Which Does Not Necessarily Have a Causal Relationship With the Treatment</measure>
    <time_frame>Baseline, 1, 4, 6, and 12 months</time_frame>
    <description>The safety and tolerability of adalimumab was assessed at each study visit. The overall number of participants experiencing serious adverse events (SAEs), non-serious adverse events (AEs) and AEs that led to discontinuation are presented. The number of participants presenting with any serious or non-serious event at each particular study visit is also reported. Note that for the incidence data participants were counted multiple times if they experienced an adverse event at more than 1 visit. For additional information see Reported Adverse Events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score (DAS 28) Index Mean Change From Baseline. The Disease Activity Score (DAS) is a Combined Index That Has Been Developed to Measure the Disease Activity in Patients With Rheumatoid Arthritis (RA).</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>The DAS 28 index measures disease activity in rheumatoid arthritis and is derived from the number swollen/tender joints, laboratory tests of inflammation, and participant assessment of global health (by marking a 10 cm line from &quot;very good&quot; to &quot;very bad&quot;). Ranges were used to classify participants, with a higher score indicating worse control of disease: Remission (&lt;= 2.6), Low Disease Activity (&gt;2.6 to &lt;=3.2), Moderate Disease Activity (&gt;3.2 to &lt;= 5.1) and High Disease Activity (&gt;5.1). The mean change in DAS 28 score from baseline to final is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score (DAS 28) Index Percentage Change From Baseline. The Disease Activity Score (DAS) is a Combined Index That Has Been Developed to Measure the Disease Activity in Patients With Rheumatoid Arthritis (RA).</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>The DAS 28 index measures disease activity in rheumatoid arthritis and is derived from the number swollen/tender joints, laboratory tests of inflammation, and participant assessment of global health (by marking a 10 cm line from &quot;very good&quot; to &quot;very bad&quot;). Ranges were used to classify participants, with a higher score indicating worse control of disease: Remission (&lt;= 2.6), Low Disease Activity (&gt;2.6 to &lt;=3.2), Moderate Disease Activity (&gt;3.2 to &lt;= 5.1) and High Disease Activity (&gt;5.1). The percentage reduction of baseline values is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Evaluation of Rheumatoid Arthritis (RA). Clinical Evaluation in the Inclusion Visit and in Each One of the Study Visits.</measure>
    <time_frame>Baseline, 1, 4, 6, and 12 months</time_frame>
    <description>The treating physician was to clinically assess each participant at each study visit and report the number of painful and swollen joints. The mean number of painful or swollen joints for participants evaluated at each time point are presented by subgroup. The number of participants evaluated in each subgroup at each time point are also reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life Quality Assessment Health Assessment Questionnaire (HAQ Questionnaire) Mean Change From Baseline.</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Quality of life was assessed using the Health Assessment Questionnaire (HAQ). The HAQ is a self-reported scale used in studies of rheumatoid arthritis to assess areas such as dressing/grooming arising, eating, walking, reach, grip, maintaining hygiene, and daily activities. The global HAQ questionnaire was scored as follows: &lt;1 = no/mild disability, 1 to 2 = moderate disability, and &gt;2 = severe disability. An increased score indicates a worsening of the disability. The mean change in global HAQ score from baseline to 12 months is reported (baseline value - final value).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life Quality Assessment Health Assessment Questionnaire (HAQ Questionnaire) Percentage Change From Baseline.</measure>
    <time_frame>Baseline and 12 Months</time_frame>
    <description>Quality of life was assessed using the Health Assessment Questionnaire (HAQ). The HAQ is a self-reported scale used in studies of rheumatoid arthritis to assess areas such as dressing/grooming arising, eating, walking, reach, grip, maintaining hygiene, and daily activities. The global HAQ questionnaire was scored as follows: &lt;1 = no/mild disability, 1 to 2 = moderate disability, and &gt;2 = severe disability. An increased score indicates a worsening of the disability. The percentage change from baseline to 12 months (12-month score minus baseline score divided by baseline score) is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological Evaluation of Rheumatoid Arthritis (RA).</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>Treating physicians were asked to obtain a structural damage assessment by performing x-rays of the hands and feet approximately 1 year after the previous structural damage assessment that was done prior to the participant entering the study. The number of participants with radiological erosions evaluated at baseline and the 12-month visit are summarized by subgroup.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">705</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>RA patients in treatment with adalimumab (Humira)</arm_group_label>
    <description>RA patients in treatment with adalimumab (Humira) at 40mg alternate weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>adalimumab (HUMIRA®)</intervention_name>
    <description>The primary objective of the study is to evaluate the safety and tolerability of adalimumab (HUMIRA®) treatment, administered both in monotherapy and combined therapy, in rheumatoid arthritis (RA) patients under usual practice conditions.</description>
    <arm_group_label>RA patients in treatment with adalimumab (Humira)</arm_group_label>
    <other_name>HUMIRA®</other_name>
    <other_name>adalimumab</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Rheumatologist consultant
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 18 years

          -  Patients who underwent adalimumab treatment at least for the previous 4 months before
             baseline visit, who have a good therapeutic response to treatment and have not been
             involved in previous clinical studies with Adalimumab or

          -  Patients who previously to the baseline visit, have been prescribe adalimumab
             complying treatment indication according to SER (Sociedad Española de Reumatología,
             Spanish Society of Rheumatology) recommendations:

          -  Patients who had provided informed consent.

          -  Patients who have been prescribed adalimumab according to the Summary of Product
             Characteristics

        Exclusion Criteria:

          -  Patients in whom a continued 12- months follow up is not anticipated.

          -  The contraindications specified in the Summary of Products Characteristics

          -  Hypersensibility to some of the components of the medication to administer.

          -  Any pathology shown by the patient that, according to medical criterion,
             contraindicates the treatment indicated in the protocol according to the Summary of
             Products Characteristics of adalimumab (HUMIRA®).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana M Ruiz-Zorrilla, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29714</name>
      <address>
        <city>A Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29061</name>
      <address>
        <city>Algeciras</city>
        <zip>11207</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29710</name>
      <address>
        <city>Almeria</city>
        <zip>04009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29719</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29054</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29698</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29063</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29718</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29720</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29706</name>
      <address>
        <city>Cadiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29052</name>
      <address>
        <city>Calella</city>
        <zip>08370</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29065</name>
      <address>
        <city>Cartagena</city>
        <zip>30203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29713</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29703</name>
      <address>
        <city>El Palmar</city>
        <zip>31120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 28607</name>
      <address>
        <city>Ferrol</city>
        <zip>15405</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 5338</name>
      <address>
        <city>Girona</city>
        <zip>17002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29701</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29711</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29705</name>
      <address>
        <city>Huelva</city>
        <zip>21080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29050</name>
      <address>
        <city>Ibiza</city>
        <zip>07800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29708</name>
      <address>
        <city>Jaen</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29709</name>
      <address>
        <city>Jerez</city>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29716</name>
      <address>
        <city>Lugo</city>
        <zip>27004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29700</name>
      <address>
        <city>Malaga</city>
        <zip>29009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29038</name>
      <address>
        <city>Manacor</city>
        <zip>07500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29712</name>
      <address>
        <city>Mataro, Barcelona</city>
        <zip>08304</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29051</name>
      <address>
        <city>Orense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29699</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29717</name>
      <address>
        <city>Pamplona</city>
        <zip>31000</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29704</name>
      <address>
        <city>Reus</city>
        <zip>43201</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29715</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29068</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30823</name>
      <address>
        <city>Seville</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29064</name>
      <address>
        <city>Tarragona</city>
        <zip>43003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29058</name>
      <address>
        <city>Valls</city>
        <zip>43800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29055</name>
      <address>
        <city>Vic</city>
        <zip>08500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29702</name>
      <address>
        <city>Vigo/Pontevedra</city>
        <zip>36200</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29697</name>
      <address>
        <city>Vigo</city>
        <zip>36204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29059</name>
      <address>
        <city>Vigo</city>
        <zip>36211</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 29053</name>
      <address>
        <city>Viladecans</city>
        <zip>08840</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2010</study_first_submitted>
  <study_first_submitted_qc>March 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2010</study_first_posted>
  <results_first_submitted>May 27, 2011</results_first_submitted>
  <results_first_submitted_qc>September 15, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 25, 2011</results_first_posted>
  <last_update_submitted>October 26, 2011</last_update_submitted>
  <last_update_submitted_qc>October 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Biologic</keyword>
  <keyword>Tumor Necrosis Factors blockers agents Monoclonal antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Adalimumab Treatment</title>
          <description>Participants with rheumatoid arthritis receiving treatment with adalimumab at 40 mg alternate weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="705"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="675"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent-to-treat (ITT) Population</title>
              <participants_list>
                <participants group_id="P1" count="591"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="590"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of effectiveness</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not reported</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adalimumab (Humira)</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="591"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Based on the ITT population minus 5 who did not report their age (586).</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.15" spread="12.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <description>Based on the ITT population (591).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gender not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Based on the ITT population (591).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time from Diagnosis of Rheumatoid Arthritis</title>
          <description>The number of years since the participant first received a diagnosis of rheumatoid arthritis. Based on the ITT population minus 91 who did not report the time since first diagnosis (500).</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.56" spread="6.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Positivity of the Rheumatoid Factor</title>
          <description>The number of participants testing positive or negative for rheumatoid factor. Based on the ITT population (591).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Positive for Rheumatoid Factor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative for Rheumatoid Factor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rheumatoid Factor Results Unknown or Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Rheumatoid Arthritis Treatment</title>
          <description>Whether or not participants had taken medication for rheumatoid arthritis within the last 5 years. Based on the ITT population (591).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Had previous rheumatoid arthritis treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No previous rheumatoid arthritis treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of Adalimumab Treatment. Adverse Events: Medical Occurrence in a Patient or Clinical Investigation Subject Administered a Pharmaceutical Product and Which Does Not Necessarily Have a Causal Relationship With the Treatment</title>
        <description>The safety and tolerability of adalimumab was assessed at each study visit. The overall number of participants experiencing serious adverse events (SAEs), non-serious adverse events (AEs) and AEs that led to discontinuation are presented. The number of participants presenting with any serious or non-serious event at each particular study visit is also reported. Note that for the incidence data participants were counted multiple times if they experienced an adverse event at more than 1 visit. For additional information see Reported Adverse Events.</description>
        <time_frame>Baseline, 1, 4, 6, and 12 months</time_frame>
        <population>This analysis was performed in the safety population of all participants who took at least 1 dose of adalimumab (675 participants).</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab Treatment</title>
            <description>Participants with rheumatoid arthritis receiving treatment with adalimumab at 40 mg alternate weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Adalimumab Treatment. Adverse Events: Medical Occurrence in a Patient or Clinical Investigation Subject Administered a Pharmaceutical Product and Which Does Not Necessarily Have a Causal Relationship With the Treatment</title>
          <description>The safety and tolerability of adalimumab was assessed at each study visit. The overall number of participants experiencing serious adverse events (SAEs), non-serious adverse events (AEs) and AEs that led to discontinuation are presented. The number of participants presenting with any serious or non-serious event at each particular study visit is also reported. Note that for the incidence data participants were counted multiple times if they experienced an adverse event at more than 1 visit. For additional information see Reported Adverse Events.</description>
          <population>This analysis was performed in the safety population of all participants who took at least 1 dose of adalimumab (675 participants).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="675"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall: Experienced a serious adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall: Experienced a non-serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall: Discontinued from study due to an AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incidence: At least 1 AE at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-- Incidence: At least 1 AE at 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-- Incidence: At least 1 AE at 4 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-- Incidence: At least 1 AE at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-- Incidence: At least 1 AE at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Incidence: At least 1 SAE at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-- Incidence: At least 1 SAE at 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-- Incidence: At least 1 SAE at 4 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-- Incidence: At least 1 SAE at 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-- Incidence: At least 1 SAE at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Activity Score (DAS 28) Index Mean Change From Baseline. The Disease Activity Score (DAS) is a Combined Index That Has Been Developed to Measure the Disease Activity in Patients With Rheumatoid Arthritis (RA).</title>
        <description>The DAS 28 index measures disease activity in rheumatoid arthritis and is derived from the number swollen/tender joints, laboratory tests of inflammation, and participant assessment of global health (by marking a 10 cm line from &quot;very good&quot; to &quot;very bad&quot;). Ranges were used to classify participants, with a higher score indicating worse control of disease: Remission (&lt;= 2.6), Low Disease Activity (&gt;2.6 to &lt;=3.2), Moderate Disease Activity (&gt;3.2 to &lt;= 5.1) and High Disease Activity (&gt;5.1). The mean change in DAS 28 score from baseline to final is presented.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Mean change from baseline to 12 months included the ITT population of 310 de novo and 281 participants treated greater than 4 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (De Novo)</title>
            <description>Those participants to whom adalimumab had been prescribed for the first time 4 months or less before the baseline visit were classified as &quot;de novo&quot; participants.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab (Treated for Greater Than 4 Months)</title>
            <description>Participants who had been taking adalimumab for 4 months or longer.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Activity Score (DAS 28) Index Mean Change From Baseline. The Disease Activity Score (DAS) is a Combined Index That Has Been Developed to Measure the Disease Activity in Patients With Rheumatoid Arthritis (RA).</title>
          <description>The DAS 28 index measures disease activity in rheumatoid arthritis and is derived from the number swollen/tender joints, laboratory tests of inflammation, and participant assessment of global health (by marking a 10 cm line from &quot;very good&quot; to &quot;very bad&quot;). Ranges were used to classify participants, with a higher score indicating worse control of disease: Remission (&lt;= 2.6), Low Disease Activity (&gt;2.6 to &lt;=3.2), Moderate Disease Activity (&gt;3.2 to &lt;= 5.1) and High Disease Activity (&gt;5.1). The mean change in DAS 28 score from baseline to final is presented.</description>
          <population>Mean change from baseline to 12 months included the ITT population of 310 de novo and 281 participants treated greater than 4 months.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="1.61"/>
                    <measurement group_id="O2" value="0.21" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Activity Score (DAS 28) Index Percentage Change From Baseline. The Disease Activity Score (DAS) is a Combined Index That Has Been Developed to Measure the Disease Activity in Patients With Rheumatoid Arthritis (RA).</title>
        <description>The DAS 28 index measures disease activity in rheumatoid arthritis and is derived from the number swollen/tender joints, laboratory tests of inflammation, and participant assessment of global health (by marking a 10 cm line from &quot;very good&quot; to &quot;very bad&quot;). Ranges were used to classify participants, with a higher score indicating worse control of disease: Remission (&lt;= 2.6), Low Disease Activity (&gt;2.6 to &lt;=3.2), Moderate Disease Activity (&gt;3.2 to &lt;= 5.1) and High Disease Activity (&gt;5.1). The percentage reduction of baseline values is presented.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>Mean reduction from baseline to 12 months was calculated for the ITT population of 310 de novo and 279 participants treated greater than 4 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (De Novo)</title>
            <description>Those participants to whom adalimumab had been prescribed for the first time 4 months or less before the baseline visit were classified as &quot;de novo&quot; participants.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab (Treated for Greater Than 4 Months)</title>
            <description>Participants who had been taking adalimumab for 4 months or longer.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Activity Score (DAS 28) Index Percentage Change From Baseline. The Disease Activity Score (DAS) is a Combined Index That Has Been Developed to Measure the Disease Activity in Patients With Rheumatoid Arthritis (RA).</title>
          <description>The DAS 28 index measures disease activity in rheumatoid arthritis and is derived from the number swollen/tender joints, laboratory tests of inflammation, and participant assessment of global health (by marking a 10 cm line from &quot;very good&quot; to &quot;very bad&quot;). Ranges were used to classify participants, with a higher score indicating worse control of disease: Remission (&lt;= 2.6), Low Disease Activity (&gt;2.6 to &lt;=3.2), Moderate Disease Activity (&gt;3.2 to &lt;= 5.1) and High Disease Activity (&gt;5.1). The percentage reduction of baseline values is presented.</description>
          <population>Mean reduction from baseline to 12 months was calculated for the ITT population of 310 de novo and 279 participants treated greater than 4 months.</population>
          <units>Percentage reduction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.34"/>
                    <measurement group_id="O2" value="0.01" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Evaluation of Rheumatoid Arthritis (RA). Clinical Evaluation in the Inclusion Visit and in Each One of the Study Visits.</title>
        <description>The treating physician was to clinically assess each participant at each study visit and report the number of painful and swollen joints. The mean number of painful or swollen joints for participants evaluated at each time point are presented by subgroup. The number of participants evaluated in each subgroup at each time point are also reported.</description>
        <time_frame>Baseline, 1, 4, 6, and 12 months</time_frame>
        <population>This analysis was conducted in the ITT population of 591 participants who had assessments at each time point. The number of de novo participants and participants treated greater than 4 months who were analyzed at each time point are given in parentheses.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (De Novo)</title>
            <description>Those participants to whom adalimumab had been prescribed for the first time 4 months or less before the baseline visit were classified as &quot;de novo&quot; participants.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab (Treated for Greater Than 4 Months)</title>
            <description>Participants who had been taking adalimumab for 4 months or longer.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Evaluation of Rheumatoid Arthritis (RA). Clinical Evaluation in the Inclusion Visit and in Each One of the Study Visits.</title>
          <description>The treating physician was to clinically assess each participant at each study visit and report the number of painful and swollen joints. The mean number of painful or swollen joints for participants evaluated at each time point are presented by subgroup. The number of participants evaluated in each subgroup at each time point are also reported.</description>
          <population>This analysis was conducted in the ITT population of 591 participants who had assessments at each time point. The number of de novo participants and participants treated greater than 4 months who were analyzed at each time point are given in parentheses.</population>
          <units>Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Painful Joints at Baseline (n=310 and n =281)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.93" spread="6.31"/>
                    <measurement group_id="O2" value="2.22" spread="3.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-- At 1 month (n=277 and n=203)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.11" spread="5.13"/>
                    <measurement group_id="O2" value="1.67" spread="3.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-- At 4 months (n=292 and n=271)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.99" spread="4.14"/>
                    <measurement group_id="O2" value="1.76" spread="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-- At 6 months (n=269 and n=267)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.53" spread="3.42"/>
                    <measurement group_id="O2" value="1.71" spread="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-- At 12 months (n=255 and n=262)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.46" spread="3.33"/>
                    <measurement group_id="O2" value="1.61" spread="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swollen Joints at Baseline (n=310 and n=281)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.19" spread="5.01"/>
                    <measurement group_id="O2" value="1.39" spread="2.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-- At 1 month (n=277 and n= 204)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.94" spread="3.89"/>
                    <measurement group_id="O2" value="1.03" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-- At 4 months (n=292 and n=272)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" spread="3.39"/>
                    <measurement group_id="O2" value="1.04" spread="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-- At 6 months (n=269 and n=266)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.53" spread="3.42"/>
                    <measurement group_id="O2" value="1.00" spread="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>-- At 12 months (n=255 and n=262)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" spread="2.83"/>
                    <measurement group_id="O2" value="0.97" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Life Quality Assessment Health Assessment Questionnaire (HAQ Questionnaire) Mean Change From Baseline.</title>
        <description>Quality of life was assessed using the Health Assessment Questionnaire (HAQ). The HAQ is a self-reported scale used in studies of rheumatoid arthritis to assess areas such as dressing/grooming arising, eating, walking, reach, grip, maintaining hygiene, and daily activities. The global HAQ questionnaire was scored as follows: &lt;1 = no/mild disability, 1 to 2 = moderate disability, and &gt;2 = severe disability. An increased score indicates a worsening of the disability. The mean change in global HAQ score from baseline to 12 months is reported (baseline value - final value).</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>The analysis was conducted for participants who had both baseline and 12-month global HAQ assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (De Novo)</title>
            <description>Those participants to whom adalimumab had been prescribed for the first time 4 months or less before the baseline visit were classified as &quot;de novo&quot; participants.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab (Treated for Greater Than 4 Months)</title>
            <description>Participants who had been taking adalimumab for 4 months or longer.</description>
          </group>
        </group_list>
        <measure>
          <title>Life Quality Assessment Health Assessment Questionnaire (HAQ Questionnaire) Mean Change From Baseline.</title>
          <description>Quality of life was assessed using the Health Assessment Questionnaire (HAQ). The HAQ is a self-reported scale used in studies of rheumatoid arthritis to assess areas such as dressing/grooming arising, eating, walking, reach, grip, maintaining hygiene, and daily activities. The global HAQ questionnaire was scored as follows: &lt;1 = no/mild disability, 1 to 2 = moderate disability, and &gt;2 = severe disability. An increased score indicates a worsening of the disability. The mean change in global HAQ score from baseline to 12 months is reported (baseline value - final value).</description>
          <population>The analysis was conducted for participants who had both baseline and 12-month global HAQ assessments.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="280"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.67"/>
                    <measurement group_id="O2" value="0.05" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Life Quality Assessment Health Assessment Questionnaire (HAQ Questionnaire) Percentage Change From Baseline.</title>
        <description>Quality of life was assessed using the Health Assessment Questionnaire (HAQ). The HAQ is a self-reported scale used in studies of rheumatoid arthritis to assess areas such as dressing/grooming arising, eating, walking, reach, grip, maintaining hygiene, and daily activities. The global HAQ questionnaire was scored as follows: &lt;1 = no/mild disability, 1 to 2 = moderate disability, and &gt;2 = severe disability. An increased score indicates a worsening of the disability. The percentage change from baseline to 12 months (12-month score minus baseline score divided by baseline score) is presented.</description>
        <time_frame>Baseline and 12 Months</time_frame>
        <population>The analysis was conducted for participants who had both baseline and 12-month global HAQ assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (De Novo)</title>
            <description>Those participants to whom adalimumab had been prescribed for the first time 4 months or less before the baseline visit were classified as &quot;de novo&quot; participants.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab (Treatment for Greater Than 4 Months)</title>
            <description>Participants who had been taking adalimumab for 4 months or longer.</description>
          </group>
        </group_list>
        <measure>
          <title>Life Quality Assessment Health Assessment Questionnaire (HAQ Questionnaire) Percentage Change From Baseline.</title>
          <description>Quality of life was assessed using the Health Assessment Questionnaire (HAQ). The HAQ is a self-reported scale used in studies of rheumatoid arthritis to assess areas such as dressing/grooming arising, eating, walking, reach, grip, maintaining hygiene, and daily activities. The global HAQ questionnaire was scored as follows: &lt;1 = no/mild disability, 1 to 2 = moderate disability, and &gt;2 = severe disability. An increased score indicates a worsening of the disability. The percentage change from baseline to 12 months (12-month score minus baseline score divided by baseline score) is presented.</description>
          <population>The analysis was conducted for participants who had both baseline and 12-month global HAQ assessments.</population>
          <units>Percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="297"/>
                <count group_id="O2" value="238"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.79"/>
                    <measurement group_id="O2" value="-0.09" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Radiological Evaluation of Rheumatoid Arthritis (RA).</title>
        <description>Treating physicians were asked to obtain a structural damage assessment by performing x-rays of the hands and feet approximately 1 year after the previous structural damage assessment that was done prior to the participant entering the study. The number of participants with radiological erosions evaluated at baseline and the 12-month visit are summarized by subgroup.</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>This analysis was conducted in the intent-to-treat population (591 participants total).</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab (De Novo)</title>
            <description>Those participants to whom adalimumab had been prescribed for the first time four months or less before the baseline visit were classified as &quot;de novo&quot; participants.</description>
          </group>
          <group group_id="O2">
            <title>Adalimumab (Treated for Greater Than 4 Months</title>
            <description>Participants who had been taking adalimumab for 4 months or longer.</description>
          </group>
        </group_list>
        <measure>
          <title>Radiological Evaluation of Rheumatoid Arthritis (RA).</title>
          <description>Treating physicians were asked to obtain a structural damage assessment by performing x-rays of the hands and feet approximately 1 year after the previous structural damage assessment that was done prior to the participant entering the study. The number of participants with radiological erosions evaluated at baseline and the 12-month visit are summarized by subgroup.</description>
          <population>This analysis was conducted in the intent-to-treat population (591 participants total).</population>
          <units>Participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="281"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total number evaluated or not reported at Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="310"/>
                    <measurement group_id="O2" value="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>a) Radiological erosions present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153"/>
                    <measurement group_id="O2" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>b) Radiological erosions not present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>c) Radiological erosions unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total evaluated or not reported at 12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="310"/>
                    <measurement group_id="O2" value="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>a) Radiological erosions present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>b) Radiological erosions not present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>c) Radiological erosions unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events that occurred during the course of the study were reported in detail on case report forms. Adverse events occurring during the study were reported up to 30 days or 5 half-lives after the last dose of adalimumab.</time_frame>
      <desc>The safety population included all participants who received at least one dose of adalimumab (675 total). While 184 participants experienced a non-serious adverse event, 18 experienced non-serious adverse events that had an incidence greater than 1% and are presented in the Other Adverse Event table.</desc>
      <group_list>
        <group group_id="E1">
          <title>Adalimumab Treatment</title>
          <description>Participants with rheumatoid arthritis receiving treatment with adalimumab at 40 mg alternate weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertransaminasaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>Bacteraemia/listeriosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>Diarrhoea/pyrexia/salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>Radius fracture/sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lupus-like syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>Sjogren's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cutaneous lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="675"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="675"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>Abbott</organization>
      <phone>1-800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

